Allergan, Medicines360 announce US FDA

The supplement currently being reviewed by FDA includes additional efficacy and safety data from an ongoing US-based phase 3 hormonal IUD trial, ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS), with 1,751 women receiving Liletta. Liletta was shown to be safe and effective for a broad range of women regardless of age, race, parity or Body Mass Index (BMI). 

Liletta was first approved in February 2015 with a two-handed inserter and received additional FDA approval in January 2016 for a new single-handed inserter. Liletta systems with the single-handed inserter are commercially available in the US as well as at a lower cost to public health clinics enrolled in the 340B Drug Pricing Program.

Liletta is a hormone-releasing system placed in a woman's uterus to prevent pregnancy for up to three years and is greater than 99% effective. Liletta is not permanent; it can be removed at any time by a healthcare provider, offering the flexibility of use for either long- or short-term contraception. Liletta can be used in women regardless of whether or not they've birthed a child. Allergan initially launched Liletta in partnership with Medicines360, a non-profit global pharmaceutical company whose mission is to provide access to medicines for women regardless of their socioeconomic status, insurance status, or geographic location.

Allergan plc, headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Medicines360, located in San Francisco, California, is a nonprofit global women's health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location.

Allergan, medicines, announce, us fda accepts snda filing